OMER Stock Analysis: Buy, Sell, or Hold?
OMER - Omeros Corporation
$12.25
-1.03 (-7.76%)
▼
5d:
-13.31%
30d:
-2.31%
90d:
+4.79%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 21, 2026
4d
Smart Money Accumulation
OMER is down 13.3% this week, but smart money is accumulating calls. Top strike: $16 2026-06-18 with 694 OI. Call ratio: 75% View Scanner →
Strength: 9.2/10
Get Alerted When OMER Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called OMER this week
80% bullish • 2 bearish
80% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OMER is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OMER is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$45.07
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$27.99
56.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OMER is currently trading at $12.25, which is considered slightly low relative to its 30-day fair value range of $12.05 to $14.70. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.5) compared to its historical average (83.9). Remarkably, the market is currently pricing in an annual earnings decline of 51.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OMER is in a strong uptrend. The price is currently testing key support at $12.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.00 (+210.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OMER is in a strong uptrend. The price is currently testing key support at $12.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.00 (+210.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$12.05 -
$14.70
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding OMER? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 210.2% below Wall St target ($38.00)
- WARNING: Recommendation downgraded due to -13.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$12.05 -
$14.70
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$12.15
Resistance Level
$15.25
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.52
Wall Street Target
$38.00
(+210.2%)
Revenue Growth (YoY)
14.9%
Valuation Discount vs History
-51.6% cheaper
PE vs Historical
9.5 vs 83.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-51.6%
(market-implied from PE analysis)
1-Year Target
$11.03
(-10%)
2-Year Target
$9.92
(-19%)
3-Year Target
$8.93
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→84)
$78.70
(+542%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 11.65 | Current EPS (TTM): $1.14
Bull Case
$16.49
(+35%)
Analyst growth 12.9%, PE expands to 12.8
Base Case
$14.99
(+22%)
Market implied 12.9%, PE stable at 11.7
Bear Case
$9.03
(-26%)
Severe decline -20.0%, PE contracts to 9.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.5 to 83.9
Stabilization Target:
$107.95
(+781.3%)
PE Expansion Potential:
+781.3%
Share & Embed Analysis
Last updated: May 15, 2026 9:28 PM ET
Data refreshes hourly during market hours. Next update: 10:28 PM
Data refreshes hourly during market hours. Next update: 10:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OMER showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
David J Borges
SELL
30000 shares
2026-01-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 57 HOLD |
Advanced OMER Option Strategies
Professional options setups generated by AI based on today's OMER price and gamma walls.
